The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect
Pharmacology Biochemistry and Behavior · 2024
DOI: 10.1016/j.pbb.2024.173776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2024. Verfasst von Harley M Buechler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rowan University, Glassboro, NJ 08028, United States. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB1, Self Administration, Ethanol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
Alcohol use disorder (AUD) affects >15 million people in the United States. Current pharmacotherapeutic treatments for AUD are only modestly effective, necessitating the identification of new targets for medications development. The cannabinoid receptor type 1 (CB1) has been a target of interest for the development of medications for substance use disorders and other compulsive disorders. However, CB1 antagonists/inverse agonists (e.g., rimonabant) have severe side effects that limit their clinical utility, including anxiety, depression, and suicide. Recent development of CB1 negative allosteric modulators (NAMs), including PSNCBAM-1, may provide an alternative mechanism of attenuating CB1 signaling with reduced side effects. PSNCBAM-1 has not yet been evaluated for effects in models of AUD. In this study, we investigated the effects of the CB1 NAM, PSNCBAM-1, in rodent models of AUD using adult male mice. PSNCBAM-1 dose-dependently attenuated oral ethanol self-administration (8 % w/v ethanol in water), significantly reducing ethanol rewards at a dose of 30 mg/kg, but not at 10 or 18 mg/kg. PSNCBAM-1 also dose-dependently attenuated palatable food self-administration (diluted vanilla Ensure), significantly reducing food rewards at 18 and 30 mg/kg PSNCBAM-1. PSNCBAM-1 did not affect conditioned place preference for 2 g/kg ethanol. These results suggest PSNCBAM-1 reduces ethanol-taking behavior via a nonspecific hypophagic effect and does not reduce the rewarding effects of ethanol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rowan University, Glassboro, NJ 08028, United States.
- Cooper Medical School of Rowan University, Camden, NJ 08103, United States.
- Rowan University, Glassboro, NJ 08028, United States. Electronic address: keckt@rowan.edu.
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
Buechler, H. M., Sumi, M., Madhuranthakam, I. M., Donegan, C., DiGiorgio, F., Acosta, A. A., Uribe, S., Rahman, M. A., Sorbello, A., Fischer, B. D., & Keck, T. M. (2024). The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2024.173776
Vancouver
Buechler HM, Sumi M, Madhuranthakam IM, Donegan C, DiGiorgio F, Acosta AA, et al. The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect. Pharmacology Biochemistry and Behavior. 2024. doi:10.1016/j.pbb.2024.173776
BibTeX
@article{Buechler2024,
author = {Buechler, Harley M and Sumi, Mousumi and Madhuranthakam, Indu Mithra and Donegan, Christa and DiGiorgio, Frank and Acosta, Alisha A and Uribe, Sarah and Rahman, Mohammad A and Sorbello, Alison and Fischer, Bradford D and Keck, Thomas M},
title = {The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect},
journal = {Pharmacology Biochemistry and Behavior},
year = {2024},
doi = {10.1016/j.pbb.2024.173776}
}
EUVIMED